Pediatric Neurology
Volume 41, Issue 1 , Pages 22-26 , July 2009

Effectiveness of the First Antiepileptic Drug in the Treatment of Pediatric Epilepsy

  • Ming-Sheng Ma, MD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • Department of Pediatrics, Chinese PLA General Hospital, Beijing, China
    • Both authors contributed equally to this work.
    • ,
  • Ying-Xue Ding, MD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • Department of Pediatrics, Chinese PLA General Hospital, Beijing, China
    • Both authors contributed equally to this work.
    • ,
  • Wang Ying, MD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • ,
  • Fang Fang, MD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • ,
  • Chang-Hong Ding, MD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • ,
  • Li-Ping Zou, MD, PhD

      Affiliations

    • Department of Neurology, Beijing Children's Hospital, The Capital Medical University, Beijing, China
    • Department of Pediatrics, Chinese PLA General Hospital, Beijing, China
    • Corresponding Author InformationCommunications should be addressed to: Dr. Zou; Department of Pediatrics; Chinese PLA General Hospital; 100853 Beijing, China 100045.

Received 13 August 2008 ,Accepted 12 January 2009.

References 

  1. Bergqvist AG. Idiopathic pediatric epilepsy syndromes. Continuum: Lifelong Learn Neurol. 2007;13(4):106–120
  2. ILAE Commission on Anti-Epileptic Drugs. Considerations on designing clinical trials to evaluate the place of new anti-epileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia. 1998;39:799–803
  3. Walker MC, Sander JW. Difficulties in extrapolating from clinical trial data to clinical practice: the case of anti-epileptic drugs. Neurology. 1997;49:333–337
  4. Shinnar S, Pellock JM. The trials and tribulations of pediatric drug trials. Neurology. 2005;65:1348–1349
  5. ILAE Commission on Classification and Terminology. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389–399
  6. ILAE Commission on Epidemiology and Prognosis. Guidelines for epidemiological studies on epilepsy. Epilepsia. 1993;34:592–596
  7. Berg AT, Levy SR, Testa FM, Shinnar S. Treatment of newly diagnosed pediatric epilepsy. Arch Pediatr Adolesc Med. 1999;153:1267–1271
  8. Tang-Wai R, Oskoui M, Webster R, Shevell M. Outcomes in pediatric epilepsy: seeing through the fog. Pediatr Neurol. 2005;33:244–250
  9. Holland KD, Glauser TA. Response to carbamazepine in children with newly diagnosed partial onset epilepsy. Neurology. 2007;69:596–599
  10. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314–319
  11. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36:1–6
  12. Marchi N, Hallene KL, Kight KM, et al. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Med. 2004;2:37
  13. Abbott NJ, Khan EU, Rollinson CM, et al. Drug resistance in epilepsy: the role of the blood–brain barrier. Novartis Found Symp. 2002;243:38–47discussion 47-53, 180-5
  14. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442–1448
  15. Anderson GD. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008;30:173–180
  16. Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD Study Group The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–1015
  17. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia. 2002;43:505–513
  18. Marson AG, Al-Kharusi AM, Alwaidh M, et al. SANAD Study Group The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016–1026
  19. Nicolson A, Appleton RE, Chadwick DW, Smith DF. The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry. 2004;75:75–79
  20. Zou LP, Lin Q, Qin J, Cai FC, Liu ZS, Mix E Topiramate Study Group. Evaluation of open-label topiramate as primary or adjunctive therapy in infantile spasms. Clin Neuropharmacol. 2008;31:86–92
  21. De Carolis P, Magnifico F, Pierangeli G, et al. Transient hypohidrosis induced by topiramate. Epilepsia. 2003;44:974–976
  22. Ziad el K, Rahi AC, Hamdan SA, Mikati MA. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology. 2005;65:1139–1140
  23. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428:486
  24. García-Morales I, Sancho Rieger J, Gil-Nagel A, Herranz Fernández JL. Antiepileptic drugs: from scientific evidence to clinical practice. Neurologist. 2007;13(6 Suppl. 1):S20–S28
  25. Karceski S, Morrell M, Carpenter D. The Expert Consensus Guideline Series: treatment of epilepsy. Epilepsy Behav. 2001;2(6):A1–50
  26. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs. 2006;8:113–129

PII: S0887-8994(09)00050-2

doi: 10.1016/j.pediatrneurol.2009.01.010

Pediatric Neurology
Volume 41, Issue 1 , Pages 22-26 , July 2009

Article Tools